new indications for glp-1 drugs fda glp 1 What to know about the era of New Molecules and Emerging Indications

The right choice depends on your individual situation

Responsible play toolsdeposit caps, timeout options, and reality checksshould be easy to find and adjust

ISSI: Two studies (998 participants) were pooled for the estimation of post-interventional ISSI values (Electronic Supplementary Fig

NP authority: Florida requires all APRNs (including PMHNPs) to work under physician protocol

Large employer health benefit plans increasingly include GLP-1 medications in formularies, though typically with prior authorization requirements and step therapy protocols

Eli Lilly is planning to submit orforglipron (Foundayo) for the treatment of T2DM in the second quarter of 2026 under the CNPV pilot program, making it possible for the drug to receive FDA approval in late 2026